Navigation Links
VIRxSYS Presents Data on HIV Vaccine at Keystone HIV Vaccine Symposia
Date:3/28/2008

HIV-Based Lentiviral vector VRX1023 Shows Promising Results

GAITHERSBURG, Md., March 28 /PRNewswire/ -- VIRxSYS Corporation will present initial scientific data for VRX1023 today at the Keystone Symposia Conference in Banff, Alberta. VRX1023 is part of a new vaccine approach -- using HIV-based lentivector as vector boost. VRX1023, an HIV antigen expressing lentiviral vector, has produced positive results in mice and in preliminary non-human primate studies. A larger, confirmatory study in Rhesus Macaques has been initiated.

"VRX1023 shows exciting promise," says Dr. Franck Lemiale, Director of Research and Development, Immunobiology for VIRxSYS. "The results from these mouse studies are very encouraging. We have seen significant long term response against HIV proteins both in terms of cellular immunity, which is mediated by T Lymphocytes, and humoral immunity, which is mediated by antibodies."

VIRxSYS takes a different approach as anti-HIV vaccine than recently publicized failed vaccines. The company is using an engineered HIV-based lentiviral vector to deliver the vaccinating antigens. In small animals, the VRX1023 lentivector has induced long-lasting cellular and humoral response against HIV. Using a DNA prime/vector boost strategy, VIRxSYS has obtained with VRX1023 greater anti-HIV immune responses than with other viral vector boost approaches currently used in the clinic, including adenoviral vectors similar to those that have been extensively tested in patients.

The ultimate goal for an anti-HIV vaccine is to suppress the impact of the initial infection, thereby significantly slowing the process of the disease. Due to the properties of the virus, a traditional total sterilizing goal may not be achievable for an anti-HIV vaccine. The next step would be to a prophylactic vaccine, which would reduce the impact of hyper-viremia in the first weeks of the infection. The aim of this vaccine is to suppress initial viremia, prevent
'/>"/>

SOURCE VIRxSYS
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
3. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
8. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
9. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
10. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
11. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Feb. 27, 2015  Boston Scientific Corporation (NYSE: ... Barclays 2015 Annual Healthcare Conference on March 10 in ... Dan Brennan , executive vice president and chief financial ... Relations, will participate in a 25-minute question and answer ... approximately 1:05 p.m. ET. Following a 5-minute break, a ...
(Date:2/27/2015)... Mass. , Feb. 27, 2015   Synageva ... ), a biopharmaceutical company developing therapeutic products for ... Disorders™ (NORD™), the European Organisation for Rare Diseases™ ... the world in observing Rare Disease Day. ... year, patient organizations, industry, and other participants conduct ...
(Date:2/27/2015)... /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: ... results for its first quarter ended December 31, 2014. ... 31, 2014, revenue was $1,336,685. Operating expenses were $1,063,393. ... per share.  Covalon,s President and CEO, ... with the significant progress we have made over the ...
Breaking Medicine Technology:Boston Scientific to Participate in the Barclays 2015 Annual Healthcare Conference 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 5Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 6Covalon Announces First Quarter Financial Results 2Covalon Announces First Quarter Financial Results 3
... 9, 2010 NewCardio, Inc. (OTC Bulletin Board: ... today that Dr. Samuel George, NewCardio,s Senior Medical Advisor, ... blinded "testing" dataset, conducted independently by the Cardiac Safety ... be held on December 9, 2010, at the headquarters ...
... Nov. 9, 2010 The addition of Cimzia® ... with a rapid clinical response, improved function and ... adult rheumatoid arthritis (RA) patients reflecting those seen ... TNF-inhibitor use).  These positive clinical trial data were ...
Cached Medicine Technology:NewCardio to Present Results of QTinno Performance on Cardiac Safety Research Consortium Blinded 'Testing' Dataset 2NewCardio to Present Results of QTinno Performance on Cardiac Safety Research Consortium Blinded 'Testing' Dataset 3NewCardio to Present Results of QTinno Performance on Cardiac Safety Research Consortium Blinded 'Testing' Dataset 4New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA) 2New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA) 3New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA) 4New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA) 5New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA) 6New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA) 7New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA) 8New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA) 9New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA) 10
(Date:3/2/2015)... Hawaii (PRWEB) March 02, 2015 Four Seasons ... is celebrating its 25th anniversary this year, having officially opened ... milestone, the luxury resort is honoring over 70 employees who ... resort -- from amongst the approximately 400 original employees. ... the Resort’s Oceanfront Lawn. , This Four Seasons ...
(Date:3/2/2015)... TX (PRWEB) March 02, 2015 What ... How should physicians request references? When are interviews scheduled, ... analyze employment opportunities?, Both training and practicing physicians who ... to these questions and more at the PracticeLink Physician ... 18. The drop-in Job Fair is from 5:30 to ...
(Date:3/2/2015)... Organic Skin Care, the leader in natural, organic and ... of the Balance Collection, an innovative treatment routine designed ... combination skin. The Balancing Masque Duo, presented in a ... products, consists of the Charcoal T-Zone Purifier and the ... a divided jar, contains both the Green Tea T-Zone ...
(Date:3/1/2015)... 2015 Security Life Insurance Company ... market, announced the addition of stand-alone individual vision ... Insurance launched today, complete with two plan options. ... the VSP® Vision Care network encompassing a strong ... space. The PrimeStar Select Vision plan will use ...
(Date:3/1/2015)... Comparing a new source of vehicle ... Quotes Pros portal this year. A broad range of ... that are being supplied through the finder at ... prices available for each policy is now provided in ... user will first be asked to present their unique ...
Breaking Medicine News(10 mins):Health News:Celebrating Four Seasons Resort Maui’s 25th Anniversary 2Health News:PracticeLink to Host a Career Advancement Workshop and Job Fair in Houston 2Health News:Éminence Organic Skin Care Launches Innovative Collection for Combination Skin 2Health News:Éminence Organic Skin Care Launches Innovative Collection for Combination Skin 3Health News:Security Life Insurance Company Launches Individual Vision Insurance Product 2Health News:United Auto Insurance Rates Now Quoted at Consumer Insurance Portal Online 2
... SEATTLE, Sept. 15 A new report issued by ... predicting medical claim costs. The research demonstrates that the commonly ... may not be the best indicator of future healthcare costs. ... calculated as a function of a person,s height and weight, and ...
... Sept. 15 /PRNewswire/ - Scientists from the Samuel Lunenfeld ... discovered a molecular link between intelligence and curiosity, which ... learning. , In a paper, published in Neuron, Dr. ... Saab, Ph.D candidate at the Lunenfeld, studied the interaction ...
... , , CALABASAS HILLS, ... strategy and technology consulting firm, is the recipient of The ... longtime support and involvement in the fight against Lou Gehrig,s ... a corporate partner for supporting and advancing the mission and ...
... Sept. 15 Pooper Scooper convention? You mean picking ... but it,s the 7th annual Pooper Scooper convention coming ... of October. The Association of Professional Animal Waste Specialists ... special event every year since its formation in 2002. ...
... , BOULDER, Colo., Sept. 15 A ... of divine descent endowed with great strength or ability." According to ... from any background who can make a positive difference in the ... To inspire young people to realize their potential for heroic greatness, ...
... prevent many adverse events, researchers say , TUESDAY, Sept. ... travel by emergency air transport, one in 20 experience ... low blood pressure or need to be resuscitated, Canadian ... risk, as are those with heart disease, traumatic injuries ...
Cached Medicine News:Health News:Milliman Report Addresses the Potential Impact of Height and Weight on Medical Costs 2Health News:Canadian researchers discover the first-ever link between intelligence and curiosity 2Health News:The ALS Association Honors Booz Allen Hamilton With the Inaugural Partnership for Success Award 2Health News:The ALS Association Honors Booz Allen Hamilton With the Inaugural Partnership for Success Award 3Health News:The ALS Association Honors Booz Allen Hamilton With the Inaugural Partnership for Success Award 4Health News:aPaws 7th Annual Pooper Scooper Convention and Turd Herding Contest - October 16-18, 2009 2Health News:Children's Author Tells America's Youth To 'Dream Big' By Inspiring The Hero In Every Child 2Health News:Children's Author Tells America's Youth To 'Dream Big' By Inspiring The Hero In Every Child 3Health News:Emergency Medical Transport By Air Carries Risks 2
... for this technique is acquired tricuspid ... for tricuspid repair are based on ... diagnosed by angiography and dye dilution ... patients with an irreversible tricuspid insufficiency, ...
... Clinic Pro Medical Billing proudly offers ... for your area of expertise. ... specific diagnosis codes and medical records ... general practice, ob/gyn, sports medicine, ophthalmology, ...
Lacrimal Intubation Set w/Retrieval Device. Size: Probes 23g x 4-1/4"....
... PLUS pachometers are acknowledged to be the ... pachometers available. These benefits are due to ... and smallest tip footprint available coupled with ... for every displayed reading. Thus corneal thickness ...
Medicine Products: